The city of Jacksonville, Florida, currently has 6 active clinical trials seeking participants for NASH - Nonalcoholic Steatohepatitis research studies.
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169
Recruiting
The study will assess the efficacy and safety of 2 dose regimens of pegozafermin for the treatment of liver fibrosis stage 2 or 3 in adult participants with MASH (previously known as nonalcoholic steatohepatitis [NASH]).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/07/2024
Locations: 89bio Clinical Study Site, Jacksonville, Florida
Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Register for Updates
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
NCT06161571
Recruiting
The aim of this study is to assess the safety and tolerability of EFX compared to placebo in subjects with non-invasively diagnosed NASH/MASH and NAFLD/MASLD.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/04/2024
Locations: Akero Clinical Study Site, Jacksonville, Florida
Conditions: NASH/MASH, NAFLD/MASLD
Register for Updates
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
NCT06215716
Recruiting
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/04/2024
Locations: Akero Clinical Study Site, Jacksonville, Florida
Conditions: NASH With Fibrosis, MASH With Fibrosis
Register for Updates
Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis
NCT05327127
Recruiting
A study to investigate the use of combination therapy with two investigational products for the treatment of adult patients with Nonalcoholic steatohepatitis (NASH).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/07/2024
Locations: ENCORE Borland Groover Clinical Research, Jacksonville, Florida
Conditions: NASH
Register for Updates
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
NCT05500222
Recruiting
This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical Outcome event.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: Jacksonville Center for Clinical Research, Jacksonville, Florida
Conditions: NASH, Cirrhosis, Liver
Register for Updates
Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
NCT04880187
Recruiting
This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (steatohepatitis) as well as fibrosis in subjects with non alcoholic steatohepatitis (NASH). as well as the safety and tolerability of AXA1125. Subjects will take one of two different doses of AXA1125 or a placebo twice daily, and a liver biopsy will be done at the beginning and end of the 48-week study.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: Westside Center for Clinical Research, Jacksonville, Florida +1 locations
Conditions: Non Alcoholic Steatohepatitis (NASH)
Register for Updates